Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christian Pecquet

Showing results (1-10 of 37) with videos related to

Pageof 4
Sort By:
Blood|December 9, 2021
Degrading JAK2 in ALL by ruxolitinib-based PROTACsStefan N Constantinescu, Christian Pecquet
Blood|January 9, 2026
Next-Generation JAK Inhibitors in the Treatment of Myeloproliferative NeoplasmsStefan N Constantinescu, William Vainchenker, Christian Pecquet
Trends in Biochemical Sciences|February 23, 2008
Mining for JAK-STAT mutations in cancerStefan N Constantinescu, Michael Girardot, Christian Pecquet
Biochemical Society Transactions|July 19, 2013
Activating Janus kinase pseudokinase domain mutations in myeloproliferative and other blood cancersStefan N Constantinescu, Emilie Leroy, Vitalina Gryshkova, et al.
Frontiers in Endocrinology|April 15, 2017
The Thrombopoietin Receptor: Structural Basis of Traffic and Activation by Ligand, Mutations, Agonists, and Mutated CalreticulinLeila N Varghese, Jean-Philippe Defour, Christian Pecquet, et al.
Plos One|June 30, 2010
JAK2 V617F constitutive activation requires JH2 residue F595: a pseudokinase domain target for specific inhibitorsAlexandra Dusa, Céline Mouton, Christian Pecquet, et al.
Blood Reviews|July 15, 2020
A p53-JAK-STAT connection involved in myeloproliferative neoplasm pathogenesis and progression to secondary acute myeloid leukemiaHarsh Goyal, Ilyas Chachoua, Christian Pecquet, et al.
International Review of Cell and Molecular Biology|February 14, 2022
Targets in MPNs and potential therapeuticsGabriel Levy, Cristina Mambet, Christian Pecquet, et al.
Blood|May 7, 2010
miR-28 is a thrombopoietin receptor targeting microRNA detected in a fraction of myeloproliferative neoplasm patient plateletsMichael Girardot, Christian Pecquet, Siham Boukour, et al.
The Journal of Biological Chemistry|March 8, 2008
Substitution of pseudokinase domain residue Val-617 by large non-polar amino acids causes activation of JAK2Alexandra Dusa, Judith Staerk, Joanne Elliott, et al.
Pageof 4

Showing results (1-10 of 37) with videos related to

Sort By:
Pageof 4
Blood|December 9, 2021
Degrading JAK2 in ALL by ruxolitinib-based PROTACsStefan N Constantinescu, Christian Pecquet
Blood|January 9, 2026
Next-Generation JAK Inhibitors in the Treatment of Myeloproliferative NeoplasmsStefan N Constantinescu, William Vainchenker, Christian Pecquet
Trends in Biochemical Sciences|February 23, 2008
Mining for JAK-STAT mutations in cancerStefan N Constantinescu, Michael Girardot, Christian Pecquet
Biochemical Society Transactions|July 19, 2013
Activating Janus kinase pseudokinase domain mutations in myeloproliferative and other blood cancersStefan N Constantinescu, Emilie Leroy, Vitalina Gryshkova, et al.
Frontiers in Endocrinology|April 15, 2017
The Thrombopoietin Receptor: Structural Basis of Traffic and Activation by Ligand, Mutations, Agonists, and Mutated CalreticulinLeila N Varghese, Jean-Philippe Defour, Christian Pecquet, et al.
Plos One|June 30, 2010
JAK2 V617F constitutive activation requires JH2 residue F595: a pseudokinase domain target for specific inhibitorsAlexandra Dusa, Céline Mouton, Christian Pecquet, et al.
Blood Reviews|July 15, 2020
A p53-JAK-STAT connection involved in myeloproliferative neoplasm pathogenesis and progression to secondary acute myeloid leukemiaHarsh Goyal, Ilyas Chachoua, Christian Pecquet, et al.
International Review of Cell and Molecular Biology|February 14, 2022
Targets in MPNs and potential therapeuticsGabriel Levy, Cristina Mambet, Christian Pecquet, et al.
Blood|May 7, 2010
miR-28 is a thrombopoietin receptor targeting microRNA detected in a fraction of myeloproliferative neoplasm patient plateletsMichael Girardot, Christian Pecquet, Siham Boukour, et al.
The Journal of Biological Chemistry|March 8, 2008
Substitution of pseudokinase domain residue Val-617 by large non-polar amino acids causes activation of JAK2Alexandra Dusa, Judith Staerk, Joanne Elliott, et al.
Pageof 4